Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vvax001 immunogenicity and safety study in patients with prior cervical premalignant or malignant lesions
NL-OMON43094Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2017
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of Vvax001 in cervical intraepithelial neoplasia (CIN), Cervical Cancer (CC) and human papillomavirus infection, sponsored by University Medical Center Groningen. Primary endpoint: Immunogenicity of Vvax001. Started Jan 2017; status: active, not recruiting.
02
Drugs
Vvax001
03
Conditions
cervical intraepithelial neoplasia (CIN)Cervical Cancer (CC)human papillomavirus infection
Beyond the preview
Go deeper on NL-OMON43094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43094.